CN Patent

CN104364231A — 用于治疗炎症和脂质异常的组合物和方法

Assigned to Cellix Bio Pvt Ltd · Expires 2015-02-18 · 11y expired

What this patent protects

本发明涉及式I和式II的化合物或其可药用的盐、以及多晶型物、溶剂化物、对映异构体、立体异构体和水合物。包含有效量的式I或式II的化合物的药物组合物可以被配制用于口服、颊部、直肠、局部、经皮、经粘膜、静脉内、肠胃外、糖浆或注射施药。此类组合物可以用于治疗高甘油三酯血症、脂肪性肝炎、胱氨酸病和炎性疾病。

USPTO Abstract

本发明涉及式I和式II的化合物或其可药用的盐、以及多晶型物、溶剂化物、对映异构体、立体异构体和水合物。包含有效量的式I或式II的化合物的药物组合物可以被配制用于口服、颊部、直肠、局部、经皮、经粘膜、静脉内、肠胃外、糖浆或注射施药。此类组合物可以用于治疗高甘油三酯血症、脂肪性肝炎、胱氨酸病和炎性疾病。

Drugs covered by this patent

remimazolam-besylate (REMIMAZOLAM BESYLATE)

Patent Metadata

Patent number: CN104364231A
Jurisdiction: CN
Classification: —
Expires: 2015-02-18
Drug substance claim: No
Drug product claim: No
Assignee: Cellix Bio Pvt Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.